



Assessment of the Potential Role of Some Inflammatory Cytokines and Chemokines in Lupus Nephritis Patients

A Thesis

Submitted for the degree of Master of Science as a Partial Fulfillment for requirements of the Master of Science in Biochemistry

 $\mathcal{B}y$

Dina Samir Elsaid Said Ahmed

(B.Sc. in Biochemistry, 2009)

Under supervision of

Prof. Dr. Kamal Ali Shalaby

Professor of Biochemistry, Biochemistry Departement Faculty of Science, Ain Shams University

Prof. Dr. Rasha Ali Abdel Noor

Assistant Professor of Internal Medicine & Rheumatology Faculty of Medicine, Tanta University

Dr. Riham Abdel Hamid Haroun

Lecturer of Biochemistry, Biochemistry Departement Faculty of Science, Ain Shams University

Biochemistry Department Faculty of Science Ain Shams University

(2019)

Abstract

Dina Samir El-said Said Ahmed. Assess the potential role of urinary TWEAK and urinary MCP-1 in systemic lupus erythematosus patients and determine their correlation with lupus nephritis activity in Egyptian patients. Biochemistry Department, Faculty of Science, Ain Shams University.

Background: There is no single biomarker to detect lupus nephritis activity. Renal biopsy is still the gold standard method but it's invasive and mainly used in the initial assessment of the patients. Urinary tumor necrosis factor-like weak inducer of apoptosis (uTWEAK), and urinary monocyte chemoattractant protein-1 (uMCP-1) can be secreted in urine of active lupus nephritis.

Patients and Methods: This is a case control study conducted on a total of 114 subjects; 92 SLE patients and 22 healthy volunteers. The patients were recruited from rheumatology unit at internal medicine department, Tanta university hospital, Tanta, Egypt. The patients and controls were subjected to full history taking, complete clinical examination, routine laboratory tests, Urinary TWEAK and urinary MCP-1 measurement, assessment of the disease activity using SLE Disease Activity Index (SLEDAI) and renal SLEDAI (r-SLEDAI) scores.

Results: Urinary TWEAK and uMCP-1 levels were higher in SLE with active nephritis group than those of other SLE groups and controls. There was a significant positive correlation between urinary TWEAK and urinary MCP-1 levels in lupus patients and proteinuria, anti-ds DNA, SLEDAI and r-SLEDAI and negatively with C3 and C4. TWEAK showed a sensitivity of 80.43% &100 % and specificity of 50%& 100% in detecting lupus activity and lupus nephritis activity respectively. Also uMCP-1 showed a sensitivity of 82.6% &100 % and specificity of 50%& 100% in detecting lupus nephritis activity respectively.

<u>Conclusions:</u> Urinary TWEAK and uMCP-1 are new, easily obtained, accurate markers with high sensitivity and specificity in detection of lupus nephritis activity.

Acknowledgement

Thanks are due first and last to **Almighty GOD** as I deeply owe **HIS** mercy, support and guidance in my whole life.

I would like to express my deep thanks and sincere gratitude to **Prof. Dr. Kamal Ali** Shalaby, Professor of Biochemistry, Faculty of Science, Ain Shams University, for his endless help, constant guidance, sincere encouragement, valuable advice and criticism. It is a great honour for me to work under his supervision throughout my postgraduate career.

It is really difficult for me to find words that can express my deep gratitude and sincere appreciation towards **Prof.Dr. Rasha Ali Abdel Noor,** Assistant Professor of Internal Medicine & Rheumatology, Faculty of Medicine, Tanta University, for her creative thinking, valuable suggestions, fruitful discussion and profound revision of the results and discussion of the manuscript.

I would like to express my extreme sincere gratitude and appreciation towards **Dr. Riham Abdel Hamid Haroun,** Lecturer of Biochemistry, Faculty of Science, Ain Shams

University, for her instructive guidance, valuable suggestions, as well as profound reading of the manuscript.

I am deeply indebted to **Prof.Dr. Mohamed Labib Salem**, Professor of Immunology, Faculty of Science, Tanta University, and the Executive Director of Center of Excellence in Cancer Research (CECR), Tanta University Teaching Hospital, and all members of (CECR), for their kind cooperation and help during keeping samples.

My deep thanks and regards to **Dr. Noha Mounir Elzoghby,** Clinical Pathology Departement, Elmenshawy hospital, Tanta, for her great effort and help me in ELISA analysis.

Dina Samir Elsaid Said Ahmed

Dedication

Every challenging work needs self efforts as well as guidance of elders especially those who were very close to our heart.

My humble effort I dedicate to my sweet and loving.

To my mother my first person in my life.

Ł

To my father without him I'm nothing.

Whose affection, love, encouragement and prays of day and night make me able to get such success and honor.

Dina Samir Elsaid Said Ahmed

Declaration

This thesis has not been submitted for a degree at this or any other university.

Dina Samir Elsaid Said Ahmed

List of Abbreviations

aa	amino acids	
ACL	Anticardiolipin	
ACR	American College of Rheumatology	
Alb	Albumin	
ALT	Alanine transferase	
ANAs	Antinuclear Antibodies	
AP-1	Activator protein 1	
APRIL	A proliferation-inducing ligand	
APS	Antiphospholipid antibody	
AST	Aspartate transferase	
AUC	Area under the curve	
BCMA	B-cell maturation antigen	
BILAG	British Isles Lupus Assessment Group	
BUN	Blood urea nitrogen	
(ds) DNA	Double strand deoxyribonucleic acid	
С3	Complement 3	

C4	Complement 4	
СВС	Complete blood count	
CCL2	Chemokine ligand 2	
CD	Cluster of differentiation	
CNS	Central nervous system	
CRP	C- reactive protein	
CVA	Cerebrovascular accident	
D.BIL	Direct Bilirubin	
DILE	Druge Induced SLE	
DNA	Deoxyribonucleic acid	
EBV	Epstein–Barr virus	
ECLAM	European Consensus Lupus Activity Measurement Index	
EDTA	Ethylenediaminetetraacetic acid	
eGFR	Estimated glomerular filtration rate	
ESR	Erythrocyte sedimentation rate	
FBS	Fasting plasma glucose	

ENA	Extractable nuclear antigens
ERK	Extracellular-signal-regulated kinase
ESRD	End-stage renal disease
EULAR	European League Against Rheumatism
Fn14	Fibroblast growth factor inducible 14
GN	Glomerulonephritis
НВ	Hemoglobin
HHV 8	Human herpes virus 8
HLA	human leukocyte antigen
HPV	Human papilloma virus
IAPP	Immunoadsorption plasmapheresis
IAS	Immunoadsorption
ICs	Immune complexs
INF- α	Interferon-alpha
IFN-γ	Interferon-gamma
INR	International normalized ratio

IQR	Interquartile Range	
IgG	Immunoglobulin G	
IL	Interleukin	
IP-10	Induced protein 10	
IRF5	Interferon regulatory factor 5	
JAK	Janus kinase	
JNK	Jun N-terminal kinases	
LAC	Lupus anticoagulant	
LDH	Lactate Dehydrogenase	
LN	Lupus Nephritis	
MAPKs	Mitogen-activated protein kinase	
MAX	Maximum	
MCP-1	Monocyte chemoattractant protein-1	
MIN	Minimum	
NF-kB p65	Nuclear factor kappa-light-chain- enhancer of activated B cells	
NK	Natural killer cells	

NSAIDs	Non- steroidal anti-inflammatory drug	
P 38	Protein 38	
PDCD1	Programmed cell death 1	
PDGF	Platelet-derived growth factor	
PI3K	Phosphoinositide 3-kinase	
PKB or Akt	Protein kinase B	
PKC	Protein kinase C	
PLAT	Platelets	
PMA	Phorbol myristate acetate	
PT	Prothrombin time	
PTPN22	Protein Tyrosine Phosphatase, Non- Receptor Type 22	
RANTES	Regulated on Activation, Normal T Cell Expressed and Secreted	
RBCs	Red blood cells	
RNP	RNP Ribonucleoprotein	
ROC	Receiver operating characteristic	
r-SLEDAI	Renal SLEDAI score	

SD	Standard Deviation	
SLAM	Systemic Lupus Activity Measure	
SLE	Systemic lupus erythematosus	
SLEDAI	Systemic Lupus Erythematosus Disease Activity Index	
SLICC	Systemic Lupus International Collabration Criteria	
Sm	Smith antigen	
SNP	Single nucleotide polymorphism	
SS	Single strand	
STAT4	Signal transducer and activator of transcription 4	
TCR	T-cell receptor	
T.BIL	Total Bilirubin	
TNF	Tumor necrosis factor	
TMB	Tetramethylbenzidine	
TP	Total Protein	
TREX1	Three prime repair exonuclease 1	

TWEAK	Tumor necrosis factor–like weak inducer of	
	apoptosis	
uMCP-1	Urinary Monocyte chemoattractant protein-	
	1	
uTWEAK	Urinary tumor necrosis factor –like weak	
	inducer of apoptosis	
UV	Ultraviolet light	
	Chia i Giot iight	
WBCs	WBCs White blood cells	
WHO	World Health Organization	

List of Tables

Table No.	Title	Page
1	1997 American College of Rheumatology Revised Criteria for Classification of Systemic Lupus Erythematosus.	17 - 18
2	2012 (Systemic Lupus International Collabration Criteria) SLICC classification criteria for SLE	19
3	The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) (SELENA SLEDAI)	20 - 21
4	International Society of Nephrology/Renal Pathology Society 2003 Classification of Lupus Nephritis	31 - 33
5	Statistical analysis of gender of the SLE patients and normal control group	71
6	Statistical analysis of age and disease duration between SLE groups and normal control group	72
7	Post-Hoc Test (LSD) of disease duration between groups	73
8	Statistical analysis of FBS levels, kidney function tests, GFR, proteinuria between SLE groups and normal control group	75 –77

List of Tables (Cont.)

Table No.	Title	Page
9	Post-Hoc Tests (Dunn's for multiple comparisons test) of GFR between groups	77
10	Post-Hoc Tests (Dunn's for multiple comparisons test) of 24 hrs proteinuria between groups	77
11	Statistical analysis of complete blood count between SLE groups and normal control group	79 - 80
12	Post-Hoc Tests (LSD) of hemoglobin between groups	80
13	Post-Hoc Tests (LSD) of RBCs between groups	80
14	Statistical analysis of ESR & CRP between SLE groups and normal control group	81
15	Post-Hoc Tests (LSD) of ESR between groups	82
16	Post-Hoc Tests (LSD) of CRP between groups	82
17	Statistical analysis of liver function tests between SLE groups and normal control group	83 – 85